Intraindividual Variability in Male Hepatic CYP3A4 Activity Assessed by Alfentanil and Midazolam Clearance

Journal of Clinical Pharmacology

Volumn 39, Issue 7, 1999, Pages 664-669

  Kharasch, Evan D ^a,b   Jubert, Carole ^b   Senn, Tauri ^b   Bowdle, T Andrew ^b   Thummel, Kenneth E ^b  

^a Anesthesiology Service   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; INTRAVENOUS ANESTHETIC AGENT; MIDAZOLAM; MIXED FUNCTION OXIDASE;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; DRUG EFFECT; ENZYMOLOGY; HUMAN; LIVER; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; REPRODUCIBILITY; TIME;

ADULT; ALFENTANIL; ANESTHETICS, INTRAVENOUS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGED; MIXED FUNCTION OXYGENASES; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 0033160860     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922008290     Document Type: Article

References (36)

1. Wrighton SA, VandenBranden M, Ring BJ: The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996;24:461-473.
2. Rendic S, Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997;29:413-580.
3. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
4. Guengerich FP: Human cytochrome P450 enzymes. In, Ortiz de Montellano PR (ed.): Cytochrome P450: Structure, Mechanism and Biochemistry. New York: Plenum, 1995;473-535.
5. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995;104:1-8.
6. Harris RZ, Benet LZ, Schwartz JB: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-239.
7. Watkins PB: Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:366-368.
8. Jones DR, Gorski JC, Hamman MA, Hall SD: Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chromatogr B 1996;678:105-111.
9. Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle TA, et al: The role of cytochrome P450 3A4 in alfentanil clearance: implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 1997;87:36-50.
10. Schuetz JD, Kauma S, Guzelian PS: Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J Clin Invest 1993;92:1018-1024.
11. Kashuba AD, Nafziger AN: Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34:203-218.
12. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Hartwell P, et al: Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556.
13. Thummel KE, Shen DD, Podoll T, Kunze KL, Trager WF, Bacchi CE, et al: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intra-individual hepatic CYP3A variability following liver transplantation. J Pharmacol Exp Ther 1994;271:557-566.
14. Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K: Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997;87:26-35.
15. Kharasch ED, Mautz D, Senn T, Lentz G, Cox K: Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol 1999; 39:275-280.
16. Olkkola KT, Backman JT, Neuvonen PJ: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-485.
17. Yun C-H, Wood M, Wood AJJ, Guengerich FP: Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P450 3A4. Anesthesiology 1992;77:467-474.
18. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED: Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995;23:490-496.
19. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al: First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
20. Klotz U, Ziegler G: Physiologic and temporal variation in hepatic elimination of midazolam. Clin Pharmacol Ther 1982;32:107-112.
21. Chauvin M, Bonnet F, Montembault C, Levron JC, Viars P: The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient. Anesth Analg 1986;65:999-1003.
22. Meuldermans W, Van Peer A, Hendrickx J, Woestenborghs R, Lauwers W, Heykants J, et al: Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 1988;69:527-534.
23. Bornemann LD, Crews T, Chen SS, Twardak S, Patel IH: Influence of food on midazolam absorption. J Clin Pharmacol 1986;26:55-59.
24. Strömberg C, Vanakoski J, Olkkola KT, Lindqvist A, Seppälä T, Laitinen LA: Exercise alters the pharmacokinetics of midazolam. Clin Pharmacol Ther 1992;51:527-532.
25. Bornemann LD, Min BH, Crews T, Rees MMC, Blumenthal HP, Colburn WA, et al: Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol 1985;29:91-95.
26. Kashuba ADM, Bertino JS Jr, Rocci ML Jr, Kulawy RW, Beck DJ, Nafziger AN: Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 1998;64:269-277.
27. Maitre PO, Vozeh S, Heykants J, Thomson DA, Stanski DR: Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology 1987;66:13-16.
28. Lemmens HJM, Burm AGL, Hennis PJ, Gladines MPPR, Bovill JG: Influence of age on the pharmacokinetics of alfentanil: gender dependence. Clin Pharmacokinet 1990;19:416-422.
29. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI: Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984;61:27-35.
30. Holazao AA, Winkler MB, Patel IH: Effects of age, gender, and oral contraceptives in intramuscular midazolam pharmacokinetics. J Clin Pharmacol 1988;28:1040-1045.
31. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD: The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64:133-143.
32. Kassai A, Toth G, Eichelbaum M, Klotz U: No evidence of a genetic polymorphism in the oxidative metabolism of midazolam. Clin Pharmacokin 1988;15:319-325.
33. Kashuba AD, Bertino JS Jr, Kearns GL, Leeder JS, James AW, Gotschall R, et al: Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 1998;63:540-551.
34. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
35. Kolars JC, Awni WM, Merion RM, Watkins PB: First-pass metabolism of cyclosporin by the gut. Lancet 1991:338:1488-1490.
36. Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-497.